MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 32.61

+2.4%

Nov 13 3:19 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (697)	6/25/2003 12:38:57 PM
From: Icebrg	Read Replies (1) of 2240

The article is available (at a cost of 10 USD) on the net. What is not clear from the PR is that the study was stopped after 14 patients had been recruited due to grade III/IV autoimmune side-effects. The original recruitment target was 21 participants. Nothing about that in the PR. Instead they wrote: In the initial cohort of 14 patients with metastatic disease as if 14 had indeed been the intended enrollment target. Well, it wasn't. The study will now continue in a second phase. I suppose that they will have to reduce the dosage used in the first phase. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next